Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
51 hedge funds and large institutions have $18.4M invested in Cidara Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 6 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.05% less ownership
Funds ownership: 1.33% → 1.28% (-0.05%)
2% less funds holding
Funds holding: 52 → 51 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
19% less capital invested
Capital invested by funds: $22.7M → $18.4M (-$4.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$324K |
| 2 |
Renaissance Technologies
New York
|
+$163K |
| 3 |
VF
Virtu Financial
New York
|
+$61.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.6K |
| 5 |
Bank of New York Mellon
New York
|
+$36.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$796K |
| 2 |
WFI
West Family Investments
Carlsbad,
California
|
-$348K |
| 3 |
Morgan Stanley
New York
|
-$135K |
| 4 |
Two Sigma Investments
New York
|
-$52.9K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$39.8K |
CDTX Hedge Fund Activity: Q4 2023 in Review
51 of the 6,868 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2023, worth a combined $18.4M — down 19% from $22.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CDTX and 5 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 13 added.
The largest buyer was GSA Capital Partners, adding an estimated $324K. The largest seller was Nantahala Capital Management, cutting an estimated $796K.
- 51 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2023, down from 52 in Q3 2023.
- Funds reported $18.4M of Cidara Therapeutics stock for Q4 2023, down 19% quarter-over-quarter.
- 5 funds opened new Cidara Therapeutics positions in Q4 2023 and 6 closed out, a net change of -1 holder.
- The largest Cidara Therapeutics buyer in Q4 2023 was GSA Capital Partners, an estimated $324K added.
- The largest Cidara Therapeutics seller in Q4 2023 was Nantahala Capital Management, an estimated $796K sold.
Based on aggregated 13F filings for Q4 2023.